Program 2019 Beijing

PROGRAM - 3rd International Keloid Symposium - Beijing, China

Time

Speaker

Title

DAY 1
Friday April 19, 2019

08:00 - 09:00
Registration and Morning Coffee
Welcome and Introduction
09:00 - 09:15
Michael H. Tirgan, MD
Honorable Prof. Shuzhong Guo
Xiaojun Wang, MD
Xiao Long, MD
Jonathan Tsao, MD
Welcome to Peking Union Medical College Hospital &
Opening of the 3rd International Keloid Symposium
Session 1
09:15 - 10:30
Chair: Michael H. Tirgan, MD
Co-Chair: Honorable Prof. Shuzhong Guo
Setting the Scene: Basic Understanding of Keloid Disorder
Michael H. Tirgan, MD
Clinical presentation of keloid disorder - an overview
Xiaojun Wang, MD
The establishment of keloid comprehensive diagnosis and treatment system
Lamont R. Jones, MD MBA
Keloid link to breast cancer outcomes suggests ethnic variation in immune response & tumor behavior
Kamal Malaker, MD PhD
Psychosocial impact of keloid disorder

10:30-10:50

Coffee Break

Session 2
10:50 - 12:30
Chair: Ernst Reichenberger, PhD
Co-Chair: Swee Tan, MBBS FRACS PhD
In Vivo and in Vitro Models for Keloid Research
Ernst Reichenberger, PhD
The use of induced pluripotent stem cells (iPSCs) in keloid research
Swee Tan, MBBS FRACS PhD
Keloid-associated lymphoid tissues in keloid lesions express vitamin D receptor
Hao Liu, MD
A comparison of apoptosis levels in keloid tissue, physiological scars, and normal skin
Jia Huang, MD
Aligned topography mediated cell elongation reverses pathological phenotype of in-vitro cultured keloid fibroblasts
Gwenaël Rolin, PhD
Fibroblast- macrophage interaction as a lever for the resolution of keloid fibrosis

12:30 – 13:30

Lunch Break

Special Session:

12:45 – 13:30

Chao-Kai Hsu, MD, PhD
Michael H. Tirgan, MD
Kannan Prema, MD

To Biopsy or Not? Pros and Cons (Joint Presentation)

Session 3
13:30 - 15:00
Chair: Frank B. Niessen, MD PhD
Co-Chair: Wei Liu, MD PhD
Overall Strategy for Management of Keloid Patients
Wei Liu, MD, PhD
Decision on the proper strategy of keloid therapy: the key for successful treatment of this disease.
Frank B. Niessen, MD PhD
The treatment of keloid and hypertrophic scars in a scar clinic, a retrospective study
Xiaoli Wu, MD
The strategy of keloid therapy-the experience of Shanghai 9th hospital
Michael H. Tirgan, MD
KRF Clinical Practice Guidelines

15:00 – 15:20

Coffee Break

Session 4

15:20: 17:00

Chair: Xiaojun Wang, MD
Co-Chair: Ferdinand Nangole, MD

Abstract Presentations

Alison T. Tran, MA
(Medical Student)
Can keloid lesions be ascribed? Examining the relationship between keloid disorder, perceived psychosocial distress, and plasma neuropeptide Y
Zhenjun Deng
(PhD Student)
The Impact of Matrix Stiffness on Fibroblast Phenotype and Keloid
Nutan Chaudhari
(PhD Student)
Topical Lysyl oxidase inhibitors to treat Keloid lesions
Seungmin Ham, PhD
Understanding activin and follistatin in keloids for developing novel treatment.
Tian Tu, MD
CUDC-907 reverses pathological phenotype of keloid fibroblasts in vitro and in vivo via dual inhibition of PI3K/Akt/mTOR signaling and HDAC2
Time
Speaker
Title

DAY 2
Saturday April 20, 2019

8:00 - 9:00
Registration and Morning Coffee

Session 1

9:00 - 10:30

Chair: Jonathan Tsao, MD

Co-Chai: Minliang Chen, MD

Radiation Therapy 1

Jonathan Tsao, MD

Overview of adjuvant radiation therapy in management of keloid lesions
Kamal Malaker, MD PhD
Primary Radiotherapy for Keloids: Optimal Time-Dose-Fraction for Maximal Resolution
Henry Weatherburn, PhD
The importance of dose / fractionation in successful treatment of keloids.
John Glees, MD, FRCR, DMRT
Discussion of four Unusual Cases of Keloid Tumours.

10:30 – 10:50

Coffee Break

Session 2

10:50 -12:30
Chair: Jouni Uitto, MD, PhD
Co-Chair: Youbin Wang, MD
Pathogenesis of Keloid Disorder
Jouni Uitto, MD, PhD
Extracellular matrix gene xpression profile in keloid fibroblasts: The effects of cellular stretching.
Youbin Wang, MD
Keloid is not scar: the immune microenvironment evidences
Frank B. Niessen, MD PhD
Reconstructed human keloid models show heterogeneity within keloid scar
Jie Yang, MD, PhD
Effects and mechanisms of N-acetyl-seryl-aspartyl-lysyl-proline inhibited the transformation of skin myfibroblasts through Rho GTPase signal.
Yingjun Su, MD
Upregulated epithelial PEDF inhibits collagen synthesis in dermal fibroblast: the implication in hypertrophic scar and keloid pathology skin myofibroblasts through Rho GTPase signal.

12:30 – 13:30

Lunch Break

Special Session:
12:45 - 13:30
Michael Tirgan, MD
Honorable Prof. Shuzhong Guo
Patricia Danielsen, MD PhD
Jonathan Tsao, MD
KRF Assembly Meeting - Everyone is Invited.

Session 3

13:30 -15:00
Chair: Minliang Chen, MD
Chair: Michael Tirgan, MD
Non-Surgical Management of Keloid Lesions
Minliang Chen, MD
Combination of Botox and Fat Transplantation as a new approach in treating keloids, report of 30 consecutive patients.
Wen Yun Ting, MD
The establishment of keloid comprehensive diagnosis and treatment system:treatment experience of non-operative treatment
Patricia Yap, MD
Re-thinking the medical management of keloids: Reflections and experiences from a busy urban clinical practice in Kingston, Jamaica
Chenjie Xu, PhD
Microneedle-based skin patch for treatment of keloid lesions
Michael Tirgan, MD
Role of cryotherapy in treatment of bulky keloid lesions

15:00 – 15:20

Coffee Break

Session 4

15:20: 17:00
Chair:Patricia L. Danielsen, MD PhD
Chair:Xiaoli Wu, MD
Abstract Presentations
Patricia L. Danielsen, MD PhD
Conducting clinical trials in keloid disease research - ethical and study design considerations
XiQiao Wang, MD
A case of earlobe keloid regression by bottom ligature and injection with corticosteroid and 5-FU
Raul Caceres, MD
Keloid research program plans for Latin America
Kannan Prema, MD
Single Surgeon's experience with keloids in India over 3 years.
Michael H. Tirgan, MD
Can laser treatment be harmful in some keloid patients? Results of an online survey.
Time
Speaker
Title

DAY 3
Sunday, April 21, 2019

8:00 - 9:00
Registration and Morning Coffee

Session 1

9:00 - 10:30

Chair: John Glees, MD, FRCR, DMRT

Co-Chair: Jie Shen, MD

Radiation Therapy 2

Patricia L. Danielsen, MD PhD

Treatment of keloids with corticosteroid injection alone or combined with surgical excision compared with ionizing radiation and other therapies: a systematic review and meta-analysis of randomized controlled trials.

Jonathan Tsao, MD

Treating Keloids with Adjuvant High-Dose Rate Brachytherapy
Jie Shen, MD
Role of radiation therapy in the treatment of keloid lesions. Experience of Peking Union Medical College Hospital
Zhifei Liu, MD
A novel treatment of keloids: Micro-plasma radio-frequency combined with hypofractionated electron-beam radiation
Ferdinand Nangole, MD
Ten years of experience with superficial radiation therapy in the treatment of keloids at the University of Nairobi. Outcome and lessons learned.

10:30-10:50

COFFEE BREAK

Session 2

10:50 -12:30

Chair: Kexin Song, MD

Co-Chair: Kamal Malaker, MD PhD

Clinical Science
Young-Jun Choi M.D.
Hidden Epidermal Cyst Formation below the Umbilical Circular Keloid
Kexin Song, MD
Hyperbaric oxygen therapy improves the effect of keloid surgery and radiotherapy by reducing the recurrence rate
Kamal Malaker, MD PhD
Biological Approach to the Treatment of Keloids: Recycled Concept and Technology.
Jinglong Cai, MD
The bodily characteristics of keloid patients

12:30 – 13:30

Lunch Break

Special Session

12:45 - 13:30

Ferdinand Nangole, MD

Michael H Tirgan, MD

Clinical presentation and challenges in treating keloid disorder in very young children.

Session 3

13:30 -15:00

Chair: Lamont R. Jones, MD, MBA

Co-Chair: Shuzhong Guo, MD

Surgery
Lamont R. Jones, MD, MBA
Update: Multi-Modality Treatment Protocol for Ear Keloids
Shuzhong Guo, MD
Skin expansion in scar/keloid repairing
Xin Xing, MD
The utility of skin flaps in the management of large keloid lesions.
Junli Shi, MD
The suture techniques: the details and improvements in plastic surgery
Young-Jun Choi, MD
Clinical outcome of 1064-nm picosecond neodymium-doped yttrium aluminum garnet laser for the treatment of hypertrophic scars

15:00 – 15:20

Coffee Break

Session 4

15:30: 17:00

Chair: Jinglong Cai, MD
Co-Chair: Gwenaël Rolin, PhD

Abstract Presentations
Haiyang Liu, MD
Preliminary investigation on the distribution of phlegm-dampness/dampness-heat tongue and TCM constitution in keloid patients
Wenbo Wang, PhD
The In vitro and ex vivo anti-keloid activity of sorafenib by antagonizing TGF-/Smad and MAPK/ERK signaling pathways
Gwenaël Rolin, PhD
Evidence about Halofuginone interest for keloid treatment
Boya Zhou, MD PhD
The anti-keloid activity of nintedanib by antagonizing TGF-/Smad and MAPK signaling pathways via lipid raft/caveolae

Closing Remarks

16:45 – 17:00

Michael H. Tirgan, MD
Honorable Prof. Shuzhong Guo
Xiaojun Wang, MD
Jonathan Tsao, MD
Patricia Danielsen, MD, PhD
Yingjun Su, MD
Closing of the 3rd International Keloid Symposium. Plans for our next symposium.